December 2020
Providence Cancer Institute is a leader in cancer immunotherapy and personalized medicine. Through our world-renowned Earle A. Chiles Research Institute, we have more than 150 research studies open for enrollment, including early phase clinical trials and novel combination therapy approaches.
Adoptive cellular therapy for head and
neck cancer
The adoptive T-cell therapy ADP-A2M4 is showing promise as a potential new treatment for patients with advanced head and neck cancer. Providence Cancer Institute is one of four centers in the US, and the only center in the Pacific Northwest, to offer a groundbreaking study of ADP-A2M4 in combination with the checkpoint inhibitor pembrolizumab.
All current open studies:
Find additional studies for many types of cancer in Multiple Tumor Types.
New studies are posted frequently - please check our website for a complete list of our current studies. For more information, call 503-215-2614.